Developmental Disabilities

Highlights Continued Progress in Early Detection and the Progression of Esophageal Disease SUFFERN, N.Y., May 2, 2025 /PRNewswire/ -- CDx Diagnostics announced today that new clinical data supporting the utility of the WATS3D test for Barrett's esophagus and dysplasia screening and surveillance has been selected for podium presentation at the 2025 Digestive Disease Week (DDW) in San Diego, the premier conference for gastroenterology professionals. This podium presentation, along with additional data featured in a separate poster presentation, highlights WATS3D's vital role in early detection, progression monitoring and risk assessment of patients at risk for Barrett's esophagus and esophageal cancer. Continue Reading WATS3D has consistently shown superior detection rates compared to conventional forceps biopsy (FB), the latter of which can miss up to 50% of cases. By sampling a broader area of mucosa and analyzing more cellular material using advanced 3D imaging, WATS3D may help gastroenterologists detect Barrett's esophagus that might otherwise go undiagnosed. New DDW 2025 data reveal WATS3D's enhanced capabilities for Barrett's detection, surveillance and risk assessment. Post this Key Events at DDW 2025: Podium Presentation: "Progression Rates of Barrett's Esophagus and Dysplasia Detected by WATS3D Are Similar to Those Diagnosed by Forceps Biopsies" Poster Presentation: "MUC2 Immunostaining Predicts Neoplastic Progression as Accurately as the Presence of Goblet Cells in Columnar-Lined Esophagus: A WATS3D Study of 3,553 Patients" Nicholas J. Shaheen, MD will deliver the podium presentation, based on a collaborative study with Dr. Michael Smith, Dr. Vivek Kaul, Mendel Singer Ph.D., and Dr. Robert Odze. "The findings validate WATS3D's role in early detection," said Dr. Shaheen. "We're excited to share these results at DDW and discuss their impact on patient care." Robert D. Odze, MD noted that "These studies advance our understanding of the biological significance of WATS3D detected lesions and their risk of progression to cancer in Barrett's esophagus." The new data shared at DDW 2025 from May 3-6 offers important clinical insights into the evolving role of WATS3D in Barrett's detection, surveillance and risk assessment. For more information, visit or contact us at [email protected]. About CDx Diagnostics CDx Diagnostics' mission is to Empower Physicians with Innovative Technology to Prevent Esophageal Cancer, One Patient at a Time. The company's proprietary diagnostic platform combines advanced computer imaging, artificial intelligence, molecular biology, and 3D cytopathology to detect precancerous changes earlier and more precisely than conventional methods. This pioneering solution has analyzed over 400,000 cases, empowering providers to identify those requiring early intervention, reduce time to treatment, and improve outcomes by detecting disease that might be missed by traditional forceps biopsies. CONTACT: Logan Garrett [email protected] 423-519-9979 SOURCE CDx Diagnostics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

PEABODY, Mass., April 28, 2025 /PRNewswire/ -- Privo Technologies, Inc., a clinical-stage biopharmaceutical company pioneering nanotechnology-based cancer therapies, is thrilled to announce the activation of multiple premier clinical sites across the United States for its ongoing CLN-004 trial. This Phase 2/3, open-label, two-arm study is evaluating the safety and efficacy of two of Privo's lead assets—PRV111 and PRV211—in patients with head and neck squamous cell carcinoma (HNSCC). The trial is now actively recruiting at the following esteemed institutions: University of Chicago Medicine (Chicago, IL) City of Hope (Los Angeles, CA) Miami Cancer Institute (Miami, FL) Cleveland Clinic (Cleveland, OH) Additional leading cancer centers are in the process of being activated and will be announced in the coming weeks. "We are honored to collaborate with some of the nation's leading head and neck oncology experts at these top-tier institutions," said Dr. Manijeh Goldberg, CEO of Privo Technologies. "Their participation underscores the potential impact of our novel therapies in transforming the treatment landscape for patients with HNSCC." About the CLN-004 Trial The CLN-004 study comprises two distinct arms: Arm 1: Evaluates PRV111, a nanoengineered, self-adhesive patch designed for the topical delivery of cisplatin directly to the tumor site. This arm targets patients with carcinoma in situ (CIS) and high-grade dysplasia of the oral cavity, aiming to improve local control and potentially reduce the extent of surgical intervention. Arm 2: Assesses PRV211, an intraoperative chemotherapy system intended for application into the resected tumor bed during surgery. This approach seeks to eliminate residual microscopic disease and reduce the risk of tumor recurrence in patients with stages T1-T4 HNSCC. Both PRV111 and PRV211 are part of Privo's proprietary PRV™ platform, which utilizes nanotechnology to enhance the locoregional delivery of chemotherapeutic agents, aiming to maximize therapeutic efficacy while minimizing systemic toxicity. About Privo Technologies Privo Technologies is dedicated to developing innovative therapies that address unmet needs in oncology, with a focus on mucosal cancers. By leveraging its PRV™ platform, Privo aims to improve patient outcomes through targeted, localized drug delivery systems. For more information about the CLN-004 clinical trial or to inquire about participation, please visit . Media Contact: Stefanie Cantin Director of Communications Privo Technologies, Inc. Email: [email protected] Phone: (978) 587-2322 Note: This press release is based on information available as of April 28, 2025. For the most current details regarding the CLN-004 trial and participating sites, please refer to Privo Technologies' official website or contact the company directly. SOURCE Privo Technologies WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Partnership underscores Baylor Genetics’ commitment to providing genetic testing as an important step to end the diagnostic odyssey for patients and families facing neurodevelopmental disordersHOUSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, today announced their collaboration with the Child Neurology Society (CNS) as an official 2025-2026 genetic testing partner. For patients and families facing neurodevelopmental disorders (NDD), epilepsy, and other neurological concerns, comprehensive genetic testing is an important step to ending the diagnostic odyssey. Many childhood-onset disorders lead providers to select comprehensive genetic testing like whole exome sequencing (WES) and whole genome sequencing (WGS). Indications for WES or WGS testing include autism spectrum disorders, developmental delay, intellectual disability, seizures and movement disorders. Baylor Genetics’ flagship rapid WGS and WES tests are among the fastest and most accurate precision diagnostic tools available, with written reports starting at five days from receipt of patient samples and high diagnostic yield of up to 40-60 percent. “Partnering with CNS underscores our commitment to helping children and families who are desperately seeking insights and answers to end their diagnostic odyssey,” said Christine Eng, M.D., Chief Medical Officer and Chief Quality Officer at Baylor Genetics. “As an official genetic testing partner for CNS, we are able to provide our comprehensive WES and WGS tests, Neurodevelopmental Disorders Panel, and other diagnostic tests to an extensive network of clinicians, patients and families, helping to deliver more answers and improve outcomes.” Baylor Genetics’ Neurodevelopmental Disorders Panel is designed for patients affected by a suspected or clinically diagnosed neurodevelopmental disorder, autism spectrum disorder, intellectual disability, and/or developmental delay. The panel analyzes 236 genes associated with these conditions, enabling robust detection of single nucleotide variants, insertions or deletions, and copy number variants at exceptional read depths. “We are delighted to welcome Baylor Genetics as a partner. Their expertise in WES, WGS, and neurodevelopmental diagnostics will be essential in delivering critical insights to patients and families who need them most,” said Monique Terrell, Executive Director and CEO of the Child Neurology Society. “As a CNS partner, we look forward to Baylor Genetics’ meaningful contributions at our Annual Meeting and other events as we collaborate to advance the care of children with neurological and developmental disorders through education, advocacy, and support for clinicians and researchers in child neurology.” Baylor Genetics’ partnership with the Child Neurology Society is part of a broader commitment to improving access to genetic testing across the U.S. The company is the core genetic sequencing partner for the National Institutes of Health’s Undiagnosed Disease Network, with more than 2,740 patient participants evaluated using WGS, WES, and other sequencing tests. Baylor Genetics also partners with the Texome Project and Project GIVE to increase access and reduce socioeconomic disparities in genetic testing. About Baylor Genetics As a pioneer of precision medicine for more than 45 years, Baylor Genetics is a leading diagnostic genomics partner offering a full spectrum of clinically relevant genetic testing, including Whole Genome Sequencing, Whole Exome Sequencing, and focused panels. Through a joint venture of H.U. Group Holdings, Inc. and Baylor College of Medicine, Baylor Genetics combines rapid and comprehensive precision diagnostics options with the support of genetic counselors to help clinicians avoid a lengthy diagnostic odyssey for their patients, guide medical management, and ensure no patient with a genetic disorder gets left behind. Baylor Genetics’ testing menu covers family planning, pregnancy, neonatal and pediatric testing, oncology, and many other specialized testing options. Located in Houston’s Texas Medical Center, Baylor Genetics serves clients in 50 states and 16 countries. Learn more about what’s next. PR Contact SVM PR baylorgenetics@svmpr.com (401) 490-9700